Showing 421-430 of 450 results for "".
- Abom Announces Sales Alliance with Essilor Prescription Safety Eyewear for RX with Advanced Anti-Fog Technologyhttps://modernod.com/news/abom-announces-sales-alliance-with-essilor-prescription-safety-eyewear-for-rx-with-advanced-anti-fog-technology/2480049/Abom, a manufacturer of anti-fogging heated goggles with integrated rechargeable batteries, announced the newest addition to its line of products, the Abom HEET RX goggle anti-fog solution. The HEET RX features the second generation of Abom’s award-winning heated goggle technology, improving upon
- US Sales of Eylea in First Quarter Best Estimateshttps://modernod.com/news/us-sales-of-eylea-in-first-quarter-best-estimates/2480174/Regeneron Pharmaceuticals reported Thursday that first-quarter sales of Eylea in the US rose 15 percent year-over-year to $984 million, besting analyst estimates of around $922 million. The company’s overall sales increased 15 percent to $1.5 billion, in line with forecasts, as net income s
- Alcon Introduces Systane Complete Solution for Dry Eyehttps://modernod.com/news/alcon-introduces-systane-complete-solution-for-dry-eye/2480262/Alcon has introduced Systane Complete, a new formula designed to provide soothing relief for every major type of dry eye. The new product joins the Systane family of dry eye drops as a first-line treatment option for people who suffer from evaporative dry eye, aqueous tear deficient dry eye, or m
- Lineage's RG6501 (OpRegen) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Meetinghttps://modernod.com/news/lineages-rg6501-opregen-phase-12a-results-will-be-featured-at-2024-angiogenesis-meeting/2482068/Lineage Cell Therapeutics announced that results showing retinal structure improvements with RG6501 (OpRegen) from a phase 1/2a clinical study (ClinicalTrials.gov Identifier:
- Lineage Cell Therapeutics Provides Update on OpRegenhttps://modernod.com/news/lineage-cell-therapeutics-provides-update-on-opregen/2481775/Lineage Cell Therapeutics provided an update on its progress with OpRegen (RG6501), its product candidate for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Lineage stated that it continues to execute its
- Phase 1/2a Results of Lineage Cell's Retinal Pigment Epithelium Cell Transplant Therapy to Be Featured at ARVO Annual Meetinghttps://modernod.com/news/phase-12a-results-of-lineage-cells-retinal-pigment-epithelium-cell-transplant-therapy-to-be-featured-at-arvo-annual-meeting/2481451/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes in addition to visual data from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.
- Lineage Cell: OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With GAhttps://modernod.com/news/lineage-cell-opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with-ga/2479160/Lineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational
- Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen for Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-presents-additional-interim-data-on-opregen-for-dry-amd-with-geographic-atrophy/2479007/Lineage Cell Therapeutics announced new positive interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal
- Lineage Cell Therapeutics to Host Expert Call Following OpRegen Data Update at 2020 AAO Meetinghttps://modernod.com/news/lineage-cell-therapeutics-to-host-expert-call-following-opregen-data-update-at-2020-aao-meeting/2478483/Lineage Cell Therapeutics will be hosting a call to discuss updated interim results from the phase 1/2a study of its lead product candidate, OpRegen, with one of the study’s principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for
- Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen for the Treatment of Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reinitiates-patient-enrollment-in-clinical-study-of-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477911/Lineage Cell Therapeutics announced that it has restarted patient enrollment in a phase 1/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD),